Defence And Security Tenders

Open House Procedure: Rivaroxaban (B01af01)

Open House Discount Contracts 2023-14

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredients Mentioned with the Possibility of Conclusion Within the Framework of the So-Called Open House Procedure.

Open House Procedure: Formoterol, Glycopyrronium Bromide and Beclometasone (R03al09)

Order Announcement - Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130 a Paragraph 8 Sgb V for Medicines with the Active Ingredient Rotigotine

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Tapentadol (Atc Code According to Who: N02ax06)

Open House Drug Discount Contracts in Accordance with Section 130A Paragraph 8C Sgb V Irinotecan, Atc L01ce02

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredients Mentioned with the Possibility of Conclusion as Part of the So-Called Open House Procedure.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredients Mentioned with the Possibility of Conclusion as Part of the So-Called Open House Procedure.

Open House Drug Discount Contracts in Accordance with Section 130A Paragraph 8C Sgb V Azacitidine, Atc L01bc07